What’s the current market cap for Genmab A/S stock?

Genmab A/S (GMAB) has a market cap of DKr97bn as of June 09, 2026.

What is the P/E ratio for Genmab A/S stock?

The price to earnings (P/E) ratio for Genmab A/S (GMAB) stock is 18.62 as of June 09, 2026.

Does Genmab A/S stock pay dividends?

No, Genmab A/S (GMAB) stock does not pay dividends to its shareholders as of June 09, 2026.

When is the next Genmab A/S dividend payment date?

Genmab A/S (GMAB) stock does not pay dividends to its shareholders.

What is the beta indicator for Genmab A/S?

Genmab A/S (GMAB) has a beta rating of 0.69. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Genmab A/S stock | DKrGMAB Share Price

07:00

09:00

11:00

12:55

14:55

About Genmab A/S

Genmab A/S is a biotechnology company based in Copenhagen, Denmark, focused on the development and commercialization of antibody therapeutics for the treatment of cancer. The company is known for its proprietary antibody technologies, such as the DuoBody® and HexaBody® platforms, which enhance the efficacy and potency of treatments. Genmab's key products include DARZALEX® (daratumumab), a monoclonal antibody used in the treatment of multiple myeloma, which is marketed in collaboration with Janssen Biotech. Founded in 1999, Genmab operates a global network of offices and research facilities, including significant operations in the United States and the Netherlands. The company's strategic positioning is bolstered by its robust pipeline of investigational drugs and strategic partnerships with pharmaceutical leaders.

Ticker

DKr GMAB

Sector

Health

Primary listing

CSE

Employees

3,088

Headquarters

Copenhagen, Denmark

Website

www.genmab.com

Genmab A/S Metrics

BasicAdvanced

kr 97bn

18.62

kr 85.03

0.69

Bulls say / Bears say

Genmab’s Q1 2026 revenue increased 25% year-over-year to $896 million, with adjusted operating profit up 23% and gross margin above 93%, demonstrating strong financial performance.

Global net sales of DARZALEX reached $3.964 billion in Q1 2026, beating analyst estimates by about $260 million and generating significant royalty income.

Genmab's late-stage pipeline includes up to seven potential registrational readouts in 2026 across EPKINLY, Rina-S, and petosemtamab, together representing more than $5 billion in peak sales potential and several upcoming catalysts.

DARZALEX royalties made up about 83% of Genmab’s Q1 revenue, making the company especially vulnerable to biosimilar competition following the FDA’s draft guidance easing biosimilar development and Shanghai Henlius’s FDA IND clearance for a subcutaneous daratumumab biosimilar.

Integrating Merus led to $45 million in acquisition-related charges in Q1 2026, and management cautioned about potential tax rate volatility during the merger process, highlighting execution risks that could put future margins under pressure.

Despite delivering strong Q1 results, GMAB shares fell nearly 3% on the earnings release day, showing investors’ concerns about valuation and uncertainty surrounding upcoming clinical results.

Data summarised monthly by Lightyear AI. Last updated on 1 Jun 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

Buy DKr GMAB

DKr

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Genmab’s Q1 2026 revenue increased 25% year-over-year to $896 million, with adjusted operating profit up 23% and gross margin above 93%, demonstrating strong financial performance.

Global net sales of DARZALEX reached $3.964 billion in Q1 2026, beating analyst estimates by about $260 million and generating significant royalty income.

Despite delivering strong Q1 results, GMAB shares fell nearly 3% on the earnings release day, showing investors’ concerns about valuation and uncertainty surrounding upcoming clinical results.

Data summarised monthly by Lightyear AI. Last updated on 1 Jun 2026.

About Genmab A/S

Ticker

Primary listing

Employees

Headquarters

Genmab A/S Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy DKr GMAB

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Genmab A/S/DKr GMAB

About Genmab A/S

Ticker

Primary listing

Employees

Headquarters

Genmab A/S Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy DKr GMAB

Upcoming events

No upcoming events

What’s the current market cap for Genmab A/S stock?

What is the P/E ratio for Genmab A/S stock?

Does Genmab A/S stock pay dividends?

When is the next Genmab A/S dividend payment date?

What is the beta indicator for Genmab A/S?

Bulls say / Bears say